Can Pharmaceutical Companies Develop a Drug for Every Cancer Patient?

Read Transcript

Pharmaceutical companies is a big firm, they like drugs in viral that you can ship around the world, pull off the shelve and treat the patients. That can be very cost effective and there're drugs, individual drugs that earn pharmaceutical companies multi-billion dollars a year.

None of them cure patients with metastatic solid cancers. We can prolong survival by months sometimes a few years, but we can't cure patient. So, I'm all for the development of better targeted therapies and chemotherapy, systemic treatments, but we've been doing this now for 75 years, and we haven't found systemic agents that can cure patients.

Now, again big farmer doesn't mind spending half a billion dollars a year and the first viral of the drug if they can make the second viral for a dollar, and ship it around the world, and these highly personalized Immune therapies. You're developing a drug unique to that patient.

So, when we treat it now, this patient reported in science six weeks ago, with a common cancer that we're seeing dramatic shrinkage in the lung and liver of that patient, now almost at a year and ongoing. We develop the unique drug that was just for that patient, we take the patients lymphocytes out.

We analyze which they are, which recognize mutations, we identify the exact population that can recognize the cancer, we grow them up, and they can effectively treat that patient, but they can't be used for other patient because the other patient have different mutations. So, we're developing a new drug for every patient, that this doesn't fit into the paradigm of the [xx].

But, it can work. And if you can find things like these that work and cure, it may not be commercially the best way for a pharmaceutical company to make money, but if it can cure patients, people will want it, and the genus of modern industry will find ways to make it commercially viable.